Priming of human peripheral blood mononuclear cells with lipopolysaccharides for enhanced arachidonic acid release and leukotriene synthesis

被引:26
作者
Surette, ME
Nadeau, M
Borgeat, P
Gosselin, J
机构
[1] CHUL, LAB VIRAL IMMUNOL, ST FOY, PQ G1V 4G2, CANADA
[2] CHUL, CTR RECH, CTR RECH RHUMATOL & IMMUNOL, ST FOY, PQ G1V 4G2, CANADA
[3] UNIV LAVAL, ST FOY, PQ G1K 7P4, CANADA
关键词
N(-)formyl-methionyl-leucyl-phenylalanine; monocytes; CD14;
D O I
10.1002/jlb.59.5.709
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In a previous study, we have shown that the ability of lipopolysaccharides (LPS) to prime isolated neutrophils for enhanced leukotriene B-4 (LTB(4)) synthesis was dependent on the presence of plasma and involved the CD14 antigen. In the present study, we have investigated the priming of human peripheral blood mononuclear cells (PBMC) with LPS for the subsequent release and metabolism of arachidonic acid, When PBMC were incubated with LPS for up to 2 h or when freshly isolated PBMC were stimulated with N-formyl-methionyl-leucyl-phenylalanine (fMLP) or with LPS alone, little or no synthesis of 5-lipoxygenase products nor arachidonic acid liberation were detected, However, the preincubation of PBMC with LPS for as Little as 5 min primed cells for the subsequent synthesis of LTB(4) upon stimulation with fMLP. Maximal priming was observed following a 15-min preincubation period and the priming effect was transient as cells preincubated with LPS for 90 min or more were no longer primed for leukotriene synthesis. Monocytes were found to be responsible for the enhanced response to fMLP since purified lymphocytes did not produce LTB(4) nor LTC(4) in contrast to monocyte-enriched suspensions. The priming for leukotriene synthesis coincided with an increased capacity for the release of free arachidonic acid as measured by mass spectrometry; LPS-primed cells released 8-15 times more arachidonic acid than unprimed cells within 1 min of stimulation with fMLP, Priming was observed with as little as 0.001-0.01 mu g LPS/mL when cells were incubated in the presence of 10% autologous plasma, Interestingly, in the absence of plasma, priming was only observed at LPS concentrations of 0.1 mu g/mL or greater, Pretreatment of cells with anti-CD14 antibodies significantly decreased the priming effect observed with 0.01 mu g/mL LPS but did not affect priming with 1 mu g/mL LPS, These results indicate that the priming of human PBMC with LPS for the subsequent synthesis of arachidonic acid metabolites via the 5-lipoxygenase pathway is dependent on plasma and CD14 at lower concentrations of LPS (0.001-0.01 mu g/mL) but not at LPS concentrations of 0.1 mu g/mL or greater.
引用
收藏
页码:709 / 715
页数:7
相关论文
共 40 条
[1]   BACTERIAL LIPOPOLYSACCHARIDES PRIME MACROPHAGES FOR ENHANCED RELEASE OF ARACHIDONIC-ACID METABOLITES [J].
ADEREM, AA ;
COHEN, DS ;
WRIGHT, SD ;
COHN, ZA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 164 (01) :165-179
[2]   THE PATHOGENESIS OF SEPSIS [J].
BONE, RC .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) :457-469
[3]  
BORGEAT P, 1990, METHOD ENZYMOL, V187, P98
[4]   BIOSYNTHESIS AND BIOLOGICAL-ACTIVITY OF LEUKOTRIENE-B4 [J].
BORGEAT, P ;
NACCACHE, PH .
CLINICAL BIOCHEMISTRY, 1990, 23 (05) :459-468
[5]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[6]   SEPARATION OF HUMAN PERIPHERAL-BLOOD MONOCYTES ON CONTINUOUS DENSITY GRADIENTS OF POLYVINYLPYRROLIDONE-COATED SILICA-GEL (PERCOLL) [J].
BRANDSLUND, I ;
RASMUSSEN, JM ;
FISKER, D ;
SVEHAG, SE .
JOURNAL OF IMMUNOLOGICAL METHODS, 1982, 48 (02) :199-211
[7]   LEUKOTRIENE-B4 IN THE IMMUNE-SYSTEM [J].
CLAESSON, HE ;
ODLANDER, B ;
JAKOBSSON, PJ .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1992, 14 (03) :441-449
[8]   ARACHIDONATE METABOLISM BY HUMAN POLYMORPHONUCLEAR LEUKOCYTES STIMULATED BY N-FORMYL-MET-LEU-PHE OR COMPLEMENT COMPONENT C5A IS INDEPENDENT OF PHOSPHOLIPASE ACTIVATION [J].
CLANCY, RM ;
DAHINDEN, CA ;
HUGLI, TE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (23) :7200-7204
[9]  
CORRALES I, 1993, IMMUNOLOGY, V80, P84
[10]  
COUTURIER C, 1991, J IMMUNOL, V147, P1899